Scientist with 14 years lab experience including 3 years in the pharmaceutical industry. Expertise in drug development, mass spectrometry, pharmacokinetics/pharmacodynamics, molecular cloning and recombinant protein production.

University of California--San Diego

Biochemistry and Cell Biology BASc '14, University of California--San Diego

University of California--Davis

Pharmacology & Toxicology PhD '24, University of California--Davis

Pharmacology | Cancer Research | Art | Music

Pharmacology

Molecular Biology

Artificial Intelligence

Safety Research

Cancer Research

Pulmonary And Respiratory Medicine

Applied Psychology

Biomaterials

Cognitive Neuroscience

Cellular And Molecular Neuroscience

Oncology

Biochemistry

Biological Psychiatry

Clinical Psychology

Rheumatology

Finance

Physiology

Organic Chemistry

Dermatology

Spectroscopy

Materials Chemistry

Immunology

Pharmaceutical Science

Surgery

Pathology And Forensic Medicine

Focus areas: cell biology, stem cell biology, cardiac biology,  cell/tissue/organ engineering, organoids, in vitro models, drug discovery, cell reprogramming, cell and gene therapy, biotechnology, biomaterials, microfluidics & microtechnologies, longevity biotechnology, experimental design.

Open & decentralized science | Lab automation | Bioengineering

Biology

Dr. Nelson is an Associate Professor with tenure in the Department of Biochemistry, Biophysics, and Molecular Biology at Iowa State University.  His lab investigates the molecular mechanisms of DNA replication and repair with a focus on infectious organisms.

Enzymology of DNA Replication and Repair

I am a cancer biologist who has devoted himself to the study of human malignancies for several years. Research is the most exciting job for me as I can enjoy scientific games every day and at the same time provide more opportunities for the treatment of cancers. My ultimate aim is to reveal pathological mechanisms underlying malignancies and transform my discoveries into the real world by saving human lives.

Associate Editor at ResearchHub Foundation

Cell Biology

Has anyone here dealt with lower transfection efficiencies in knockout cell lines than in the wild-type? I'm working with a U2OS  (human osteosarcoma) cell line which harbors a knockout for a protein I'm studying, knocked out using Cas9 RNP. I'm transfecting using Lipofectamine 3000 and an EGFP bearing plasmid (pcDNA3.1). I have performed an optimization screen of different concentrations and ratios of Lipofectamine 3000/DNA, and our knockout consistently has much lower transfection efficiency than the wild-type. It followed the same trend as the wild-type throughout the screen but just never generated as many transfected cells. I'm asking this because I want to transfect my cells with a FLAG tagged construct followed by co-immunoprecipitation, and transfecting the knockout cells to a higher degree is essential to that. I'm seeing ~5% transfection efficiency at max right now. Really hoping I won't have to resort to FACS to separate out transfectants. Looking For: Insight into what is going on, and how I can fix it. Protocols pertaining to this or papers which are informative about this issue would be excellent. Note: Multiple bounties are up for grabs if more than one response hits the mark. 

[Bounty 200 RSC] Looking for Help With Low Transfection Efficiency in KO vs. WT Cells

[Bounty 200 RSC] Looking for Help With Low Transfection Efficiency in KO vs. WT Cells

Scan to connect with one of our mobile apps

Coinbase Wallet app

Coinbase app

Or try the Coinbase Wallet browser extension